Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/1999
04/07/1999EP0906243A1 Dissolvable oxides for biological applications
04/07/1999EP0906122A2 Activated linkers and methods for making and purifying the same
04/07/1999EP0906110A1 Dna vaccine formulations
04/07/1999EP0906107A1 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
04/07/1999EP0906098A1 Virginiamycin mixture
04/07/1999EP0906092A1 Pharmaceutical compositions based on diclofenac
04/07/1999EP0906089A2 Buccal delivery system
04/07/1999EP0906086A1 Composition
04/07/1999EP0906069A1 Tissue re-surfacing with hydrogel-cell compositions
04/07/1999EP0906015A1 Liver retention clearing agents
04/07/1999EP0810855A4 Polyalkylene block copolymers as surface modifiers for nanoparticles
04/07/1999EP0764020B1 Transdermal drug delivery system
04/07/1999EP0742715B1 Oral liquid compositions containing paroxetine resinate
04/07/1999EP0656883B1 Cationic lipids
04/07/1999EP0538313B1 Topical ophthalmic suspensions
04/07/1999CN1213316A Polymeric delivery of radionuclides and radiopharmaceuticals
04/07/1999CN1213301A Sustained-release metal valproate tablets
04/07/1999CN1213299A Solid formulations containing trehalose
04/07/1999CN1213297A Compositions for treating hair or skin
04/07/1999CN1213295A Aqueous product comprising oil microdroplets stabilized by in-situ polymerized binyl monomer and thickening agent
04/07/1999CN1213282A Oral peptide pharmaceutical products
04/07/1999CN1212890A Compositions useful for transferring therapeutically active substances into target cell, and their use in gene therapy
04/07/1999CN1212869A Fixed-dose association of angiotensin-converting enzyme inhibitor and of calcium channel antagonist, method for preparation and use thereof in treatment of cardivas cular illnesses
04/06/1999US5892071 Cationic transport reagents
04/06/1999US5892043 Camptothecin derivatives
04/06/1999US5892026 Supersaturated composition prepared by dissolving syrup at ambient temperature with one or more saccharides as crystal growth inhibitors in equal or greater amount; uncontaminated with bacteria; for foods, feeds, drugs, cosmetics
04/06/1999US5892019 Production of a single-gene-encoded immunoglobulin
04/06/1999US5891920 Medicinal adjuvants consisting of N-subsitituted-o-toluidine derivatives, and percutaneously absorbable preparations comprising the adjuvants
04/06/1999US5891914 Bioactive topical siloxane compositions having enhanced performance and safety
04/06/1999US5891911 Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
04/06/1999US5891854 Moisturizers
04/06/1999US5891845 Drug delivery systems utilizing liquid crystal structures
04/06/1999US5891735 Chemiluminescence
04/06/1999US5891704 Method to produce high levels of methioninase
04/06/1999US5891689 Heme-bearing microparticles for targeted delivery of drugs
04/06/1999US5891478 Composition for sustained release of human growth hormone
04/06/1999US5891475 Non-liquid hydrophilic core, an external layer comprised of lipid compounds grafted on the core by covalent bonds. enhancing the activity of the polypeptide cellular mediator.
04/06/1999US5891473 Toothpastes
04/06/1999US5891472 Topical treatment for administering nitric oxide in lipid based carriers
04/06/1999US5891468 Fusogenic liposome compositions and method
04/06/1999US5891467 Encapsulation and release of active compounds
04/06/1999US5891462 Composition for transdermal administration of an estrogen
04/06/1999US5891457 Treating menorrhagia with silver nitrate composition
04/06/1999US5891454 Anti-cancer drug and special tumor necrotizing agent
04/06/1999CA2248838A1 An intravenous form of thalidomide for the therapy of immunological diseases
04/06/1999CA2155005C Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
04/06/1999CA2151774C Skin disinfecting formulations
04/06/1999CA2146192C Polyionic insoluble hydrogels comprising xanthan
04/06/1999CA2140255C Polyarylates containing derivatives of the natural amino acid l-tyrosine
04/06/1999CA2095836C Cytokine immunoconjugates
04/06/1999CA2074320C Process for the preparation of microspheres made of a biodegradable polymeric material
04/06/1999CA2064190C Process for preparation of an oil in water emulsion of a drug
04/06/1999CA2061824C Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
04/06/1999CA2050045C Pharmaceutical, vaginal applicable preparation and a process for its preparation
04/01/1999WO1999015687A1 Multicomponent polynucleotide complex for high efficiency cell transfection
04/01/1999WO1999015653A2 Tie ligand homologues
04/01/1999WO1999015628A1 Methods and compositions for binding hematopoietic stem cells
04/01/1999WO1999015542A2 Linker nucleoside, and production and use of the same
04/01/1999WO1999015528A1 Acidic addition salts of morphine alkaloids and the application thereof
04/01/1999WO1999015509A2 Cyclohexyl and heterocyclyl nucleoside derivatives, method for producing these derivatives, and the use of the derivatives and their oligomers or conjugates in pairing and/or testing systems
04/01/1999WO1999015210A2 Bioadhesive compositions and methods for topical administration of active agents
04/01/1999WO1999015201A1 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
04/01/1999WO1999015193A1 LIQUID INTERFERON-β FORMULATIONS
04/01/1999WO1999015171A1 Nicotine compositions and methods of formulation thereof
04/01/1999WO1999015165A1 Topical non-steroidal anti-inflammatory drug composition
04/01/1999WO1999015156A1 Inhibition of crystallization in transdermal devices
04/01/1999WO1999015155A1 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
04/01/1999WO1999015154A1 Methods for fabricating polymer-based controlled release preparations
04/01/1999WO1999015150A1 Inorganic-polymer complexes for the controlled release of compounds including medicinals
04/01/1999WO1999015147A2 Use of alkylmonoglucosides as molecular vectors
04/01/1999WO1999002567A3 Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
04/01/1999WO1999002545A3 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
04/01/1999WO1999002186A3 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
04/01/1999WO1999002182A3 Non-aqueous vaccines
04/01/1999WO1999002120A3 Compositions and methods for reversibly increasing permeability of biomembranes
04/01/1999WO1998056370A3 Therapeutic nanospheres
04/01/1999WO1998052573A9 Triterpene saponin analogs having adjuvant and immunostimulatory activity
04/01/1999WO1998051787A3 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
04/01/1999WO1998039464A8 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
04/01/1999WO1998039363A3 Immunotoxins and methods of inducing immune tolerance
04/01/1999WO1998024482A3 Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
04/01/1999DE19741739A1 Supramolekulares Paarungssystem, dessen Herstellung und Verwendung Supramolecular mating system, its preparation and use
04/01/1999CA2304961A1 Methods and compositions for binding hematopoietic stem cells
04/01/1999CA2304599A1 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
04/01/1999CA2304191A1 Topical non-steroidal anti-inflammatory drug composition
04/01/1999CA2304129A1 Tie ligand homologues
04/01/1999CA2304042A1 Nicotine compositions and methods of formulation thereof
04/01/1999CA2303527A1 Linker nucleoside, its preparation and use
04/01/1999CA2301641A1 Supramolecular pairing system, its preparation and use
03/1999
03/31/1999EP0905254A2 DNA vector associated with biocompatible low molecular weight polyethyleneimines
03/31/1999EP0905138A1 Crystals of maltitol of a particular form, crystalline compositions containing them and processes for their preparation
03/31/1999EP0904778A1 Stabilized percutaneous absorption preparation
03/31/1999EP0904693A1 Pseudoplastic film-forming acidic chlorite composition as teat dip
03/31/1999EP0904373A1 Targeted delivery of genes encoding interferon
03/31/1999EP0904294A1 Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (vip)
03/31/1999EP0904113A2 Microencapsulated fluorinated gases for use as imaging agents
03/31/1999EP0904112A1 Composition comprising interleukin-1 inhibitor and controlled release polymer
03/31/1999EP0904111A1 Cosmetic and/or pharmaceutical emulsions containing behenyl derivatives
03/31/1999EP0904109A1 Targeting macromolecular prodrugs to t lymphocytes
03/31/1999EP0904107A1 Immunoglobin-like domains with increased half lives